DPYD Antibody (D-8): sc-271308

DPYD Antibody (D-8) is a mouse monoclonal IgG2b antibody that detects dihydropyrimidine dehydrogenase (DPYD) in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). DPYD plays a crucial role in the metabolism of pyrimidines, catalyzing the first rate-limiting step in the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine. This enzymatic activity is vital as a deficiency in DPYD can lead to the accumulation of uracil and thymine, which has been associated with neurological diseases and can complicate the treatment of cancer patients using certain pyrimidine analogs. Furthermore, DPYD is integral to the metabolic pathway of the anticancer agent 5-fluorouracil (5-FU), influencing both its efficacy and potential toxicity. Variations in DPYD expression, often due to transcriptional alterations such as hypermethylation of the DPYD promoter, can significantly impact patient responses to 5-FU treatment, making the study of DPYD essential for understanding and mitigating adverse drug reactions. Anti-DPYD antibody (D-8) is an invaluable tool for researchers investigating the role of this enzyme in cancer therapy and metabolic disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DPYD Antibody (D-8) References:

1. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.  |  Ticha, I., et al. 2009. Cancer Chemother Pharmacol. 64: 615-8. PMID: 19288105
2. P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting.  |  Gokare, P., et al. 2017. Sci Rep. 7: 9711. PMID: 28851987
3. Dihydropyrimidine dehydrogenase (DPYD) gene c.1627A>G A/G and G/G genotypes are risk factors for lymph node metastasis and distant metastasis of colorectal cancer.  |  Zeng, J., et al. 2021. J Clin Lab Anal. 35: e24023. PMID: 34612540
4. Concordance of Blood-Based and Normal Tissue-Based Dihydropyrimidine Dehydrogenase (DPYD) Genotyping.  |  Morelli, C., et al. 2022. Oncologist. 27: e420-e421. PMID: 35325223
5. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.  |  White, C., et al. 2022. Clin Pharmacol Ther. 112: 791-802. PMID: 35607723
6. Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays.  |  De Luca, O., et al. 2022. Int J Mol Sci. 23: PMID: 36430399
7. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.  |  Etienne-Grimaldi, MC., et al. 2023. Eur J Cancer. 181: 3-17. PMID: 36621118
8. Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing.  |  Turner, AJ., et al. 2024. Clin Transl Sci. 17: e13699. PMID: 38129972
9. Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD).  |  Ambrodji, A., et al. 2024. Int J Mol Sci. 25: PMID: 39062841
10. Dihydropyrimidine Dehydrogenase Deficiency (DPYD) Genotyping-Guided Fluoropyrimidine-Based Adjuvant Chemotherapy for Breast Cancer. A Cost-Effectiveness Analysis.  |  Abushanab, D., et al. 2025. Clin Drug Investig. 45: 151-163. PMID: 39885055

The preferred DPYD antibody is DPYD Antibody (A-5): sc-376712.